Introduction: Psoriasis is a chronic inflammatory skin disease often associated with type 2 diabetes and other metabolic disorders. GLP-1 receptor agonists (GLP-1 RAs), used for glycemic control and weight management in diabetes, have shown potential anti-inflammatory effects. Aim of the study: This study aimed to evaluate the impact of GLP-1 RAs on psoriasis activity in patients with type 2 diabetes who were already receiving topical or biological therapies for psoriasis. Methods: A retrospective analysis was conducted on 14 patients with psoriasis and type 2 diabetes treated with GLP-1 RAs for 3 to 45 months. Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI), and changes in BMI were recorded. The correlation between PASI improvement, BMI reduction, and treatment duration was analyzed from T1(introduction of GLP-1 RA) to T2b (last visit). Results: A significant reduction in PASI was observed in the majority of patients, with a mean reduction of 1.25 points, corresponding to a mean improvement of 38.7% from T1 and T2. Five patients experienced a weight loss exceeding 10% of their baseline body weight. However, no statistically significant correlation was found between BMI reduction and PASI improvement, suggesting that GLP-1 RAs exert anti-inflammatory effects independent of weight loss. Conclusion: GLP-1 RAs demonstrate a moderate but significant benefit in reducing psoriasis severity in patients with type 2 diabetes, irrespective of BMI changes. This study highlights the potential anti-inflammatory role of GLP-1 RAs, particularly as an adjunct therapy for psoriasis, supporting their potential role as a complementary treatment option for psoriatic patients with diabetes.

Glucagon-like peptide-1 receptor agonist therapy in patients with psoriasis and diabetes mellitus type 2.

MIOSO, GUIDO
2022/2023

Abstract

Introduction: Psoriasis is a chronic inflammatory skin disease often associated with type 2 diabetes and other metabolic disorders. GLP-1 receptor agonists (GLP-1 RAs), used for glycemic control and weight management in diabetes, have shown potential anti-inflammatory effects. Aim of the study: This study aimed to evaluate the impact of GLP-1 RAs on psoriasis activity in patients with type 2 diabetes who were already receiving topical or biological therapies for psoriasis. Methods: A retrospective analysis was conducted on 14 patients with psoriasis and type 2 diabetes treated with GLP-1 RAs for 3 to 45 months. Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI), and changes in BMI were recorded. The correlation between PASI improvement, BMI reduction, and treatment duration was analyzed from T1(introduction of GLP-1 RA) to T2b (last visit). Results: A significant reduction in PASI was observed in the majority of patients, with a mean reduction of 1.25 points, corresponding to a mean improvement of 38.7% from T1 and T2. Five patients experienced a weight loss exceeding 10% of their baseline body weight. However, no statistically significant correlation was found between BMI reduction and PASI improvement, suggesting that GLP-1 RAs exert anti-inflammatory effects independent of weight loss. Conclusion: GLP-1 RAs demonstrate a moderate but significant benefit in reducing psoriasis severity in patients with type 2 diabetes, irrespective of BMI changes. This study highlights the potential anti-inflammatory role of GLP-1 RAs, particularly as an adjunct therapy for psoriasis, supporting their potential role as a complementary treatment option for psoriatic patients with diabetes.
2022
Glucagon-like peptide-1 receptor agonist therapy in patients with psoriasis and diabetes mellitus type 2.
psoriasis
GLP-1RA
diabetes
File in questo prodotto:
File Dimensione Formato  
Mioso_Guido.pdf

accesso riservato

Dimensione 1.33 MB
Formato Adobe PDF
1.33 MB Adobe PDF

The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12608/81461